Metraipolis › archive › dc_280d1ee3c8ee
Continuous quality evaluation of the Asanté rapid test for recent infection for robust kit lot quality verification — Europe PMC PMID:38743714
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/38743714
- DOI
- 10.1371/journal.pgph.0003195
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T18:31:22.823Z
- SHA-256 of the archived text
27747a60f837ba3ab836bc1897ebfe1d221cee81e6560a36cfc4aebd46326458- Stable URL of this page
https://metraipolis.com/documento/dc_280d1ee3c8ee
How to cite
Continuous quality evaluation of the Asanté rapid test for recent infection for robust kit lot quality verification — Europe PMC PMID:38743714 — Europe PMC (en), https://europepmc.org/article/MED/38743714 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_280d1ee3c8ee (Metraipolis archive dc_280d1ee3c8ee, sha256 27747a60f837ba3ab836bc1897ebfe1d221cee81e6560a36cfc4aebd46326458)
BibTeX
@misc{dc280d1ee3c8ee,
title = {Continuous quality evaluation of the Asanté rapid test for recent infection for robust kit lot quality verification — Europe PMC PMID:38743714},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/38743714},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_280d1ee3c8ee; sha256 27747a60f837ba3ab836bc1897ebfe1d221cee81e6560a36cfc4aebd46326458},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38743714. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The Sedia Biosciences Asanté rapid test for recent infection (RTRI) can identify HIV infections and characterize HIV-1 as recent or long-term infection via the positive verification (V) line and long-term line (LT) line, respectively. Tracking with Recency Assays to Control the Epidemic (TRACE) program uses RTRI assays. Successful implementation of TRACE requires high-quality test performance. The goal of this study is to evaluate the additional quality practices established for new kit lots prior to field use. Asanté lot quality control data from the manufacturer is reviewed by the Centers for Disease Control and Prevention International Laboratory Branch (CDC-ILB) in the Division of Global HIV and TB using. If a lot passes manufacturer quality control and CDC-ILB review, test kits are sent to CDC-ILB for further evaluation. Evaluation by CDC includes inter-rater reliability and linear regressions comparing the V and LT lines against reference data as well as V and LT line data between testers. A Bland-Altman analysis was conducted to assess bias and systematic error. Overall, CDC-ILB passed 29 (91%) out of 32 Sedia Biosciences Asanté kit lots that initially passed manufacturing quality control from July 2017 to May 2020. Regression analyses demonstrate that test kits are performing as expected with consistent R2≥0.92 for both V and LT lines. On average, inter-rater reliability kappa was 0.9, indicating a strong level of agreement. Bland-Altman analyses demonstrate high agreement with little to no systematic error and bias. Ongoing evaluation of new RTRI kit lots is important to ensure high quality test performance. Rejecting 9% of kit lots highlight the importance of continuing to work with manufacturers to ensure consistent kit production and quality assurance (QA) activities. Investing in effective QA measures, conducting both pre- and post-market performance data reviews, could help improve RTRI accuracy and outcomes in similar testing programs. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLOS global public health, 2024 (prima pubblicazione 2024-05-14). Identificativi: PMID 38743714 · PMCID PMC11093390 · DOI 10.1371/journal.pgph.0003195. Pagina: https://europepmc.org/article/MED/38743714 — https://doi.org/10.1371/journal.pgph.0003195. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T16:55:36.185Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.